Advertisement

Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor

  • Marco Grasso
  • Marco Boscaro
  • Carla Scaroni
  • Filippo Ceccato
Review Article
  • 24 Downloads
Part of the following topical collections:
  1. Secondary Hypertension

Abstract

Prevalence of arterial hypertension is up to 30–40% in epidemiological studies, it increases with aging and affects the cardiovascular risk. Essential form of hypertension is the most frequent; however, 5–10% of patients are affected by a specific and potentially reversible cause of increased blood pressure levels, called secondary hypertension. In general, all patients with young onset-age (< 40–50 years) or resistant hypertension should be screened for secondary forms. Among them, primary aldosteronism, Cushing’s Syndrome and pheochromocytoma are the most common cause of endocrine hypertension associated with an autonomous secretion of adrenal hormones, often secondary to a tumor (either mono- or bi-lateral, or not always in the adrenals). Their diagnosis could be challenging, especially in patients with hypertension as the first (and/or isolated) clinical manifestation. Moreover, they are all rare form of hypertension, therefore a correct screening with a sensitive test is mandatory, to refer quickly the patients to an Endocrine Unit. In this short review we pinpoint our attention to these adrenal-related secondary form of hypertension, describing in a concise way their first-line screening procedures.

Keywords

Hypertension Cushing syndrome Primary aldosteronism Pheochromocytoma 

Notes

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.

Funding

This study did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Research involving human participants and patient consent

Informed consent to describe patients’ history has been obtained.

References

  1. 1.
    Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.  https://doi.org/10.1093/eurheartj/eht151.CrossRefPubMedGoogle Scholar
  2. 2.
    Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–54.  https://doi.org/10.1093/eurheartj/eht534.CrossRefPubMedGoogle Scholar
  3. 3.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26.  https://doi.org/10.1161/CIRCULATIONAHA.108.189141.CrossRefPubMedGoogle Scholar
  4. 4.
    El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol (Lausanne). 2016;7(June):1–10.  https://doi.org/10.3389/fendo.2016.00072.CrossRefGoogle Scholar
  5. 5.
    Ceccato F, Scaroni C, Boscaro M. The adrenal glands. In: Belfiore A, LeRoith D, editors. Principles of endocrinology and hormone action, Chap 15. Switzerland: Springer; 2016. p. 387–421.  https://doi.org/10.1007/978-3-319-27318-1_16-1.Google Scholar
  6. 6.
    Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50.  https://doi.org/10.1016/S2213-8587(17)30319-4.CrossRefPubMedGoogle Scholar
  7. 7.
    Cicala MV, Mantero F. Hypertension in Cushing’s Syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92(1):44–9.  https://doi.org/10.1159/000314315.CrossRefPubMedGoogle Scholar
  8. 8.
    Isidori A, Graziadio C, Paragliola R, et al. The hypertension of Cushingʼs syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015;33(1):44–60.  https://doi.org/10.1097/HJH.0000000000000415.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Eisenhofer G. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49.  https://doi.org/10.1124/pr.56.3.1.CrossRefPubMedGoogle Scholar
  10. 10.
    Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab. 2017;32(2):152.  https://doi.org/10.3803/EnM.2017.32.2.152.CrossRefGoogle Scholar
  11. 11.
    Funder J, Carey R, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.  https://doi.org/10.1210/jc.2015-4061.CrossRefPubMedGoogle Scholar
  12. 12.
    Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.  https://doi.org/10.1210/jc.2008-0125.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.  https://doi.org/10.1210/jc.2014-1498.CrossRefPubMedGoogle Scholar
  14. 14.
    Sabbadin C, Fallo F. Hyperaldosteronism: screening and diagnostic tests. High Blood Press Cardiovasc Prev. 2016;23(2):69–72.  https://doi.org/10.1007/s40292-016-0136-5.CrossRefPubMedGoogle Scholar
  15. 15.
    Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19–29.  https://doi.org/10.1530/EJE-17-0990.CrossRefPubMedGoogle Scholar
  16. 16.
    Cicala MV, Mantero F. Primary aldosteronism: what consensus for the diagnosis. Best Pract Res Clin Endocrinol Metab. 2010;24(6):915–21.  https://doi.org/10.1016/j.beem.2010.10.007.CrossRefPubMedGoogle Scholar
  17. 17.
    Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9.  https://doi.org/10.1210/jc.2005-1733.CrossRefPubMedGoogle Scholar
  18. 18.
    Fischer E, Adolf C, Pallauf A, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab. 2013;98(6):2513–20.  https://doi.org/10.1210/jc.2012-3934.CrossRefPubMedGoogle Scholar
  19. 19.
    Hanslik G, Wallaschofski H, Dietz A, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol. 2015;173(5):665–75.  https://doi.org/10.1530/EJE-15-0450.CrossRefPubMedGoogle Scholar
  20. 20.
    Beuschlein F, Mulatero P, Asbach E, et al. The SPARTACUS Trial: controversies and unresolved issues. Horm Metab Res. 2017;49(12):936–42.  https://doi.org/10.1055/s-0043-120524.CrossRefPubMedGoogle Scholar
  21. 21.
    Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147(7):1289–93. http://www.ncbi.nlm.nih.gov/pubmed/3606286.CrossRefGoogle Scholar
  22. 22.
    Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12(5):609–15. http://www.ncbi.nlm.nih.gov/pubmed/7930562.CrossRefGoogle Scholar
  23. 23.
    Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2018;6(3):249–52.  https://doi.org/10.4158/ep.6.3.249.CrossRefGoogle Scholar
  24. 24.
    Wyszyńska T, Cichocka E, Wieteska-Klimczak A, Jobs K, Januszewicz P. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr. 1992;81(3):244–46. http://www.ncbi.nlm.nih.gov/pubmed/1511199.CrossRefGoogle Scholar
  25. 25.
    Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44.  https://doi.org/10.1210/jcem.85.2.6372.CrossRefPubMedGoogle Scholar
  26. 26.
    Lafont M, Fagour C, Haissaguerre M, et al. Per-operative hemodynamic instability in normotensive patients with incidentally discovered pheochromocytomas. J Clin Endocrinol Metab. 2015;100(2):417–21.  https://doi.org/10.1210/jc.2014-2998.CrossRefPubMedGoogle Scholar
  27. 27.
    Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G34.  https://doi.org/10.1530/EJE-16-0467.CrossRefGoogle Scholar
  28. 28.
    Shimon I. Screening for Cushing’s syndrome: is it worthwhile? Pituitary. 2015;18(2):201–5.  https://doi.org/10.1007/s11102-015-0634-9.CrossRefPubMedGoogle Scholar
  29. 29.
    Ceccato F, Boscaro M. Cushing’s syndrome: screening and diagnosis. High Blood Press Cardiovasc Prev. 2016;23(3):209–15.  https://doi.org/10.1007/s40292-016-0153-4.CrossRefPubMedGoogle Scholar
  30. 30.
    Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121–31.  https://doi.org/10.1210/jc.2009-0612.CrossRefPubMedGoogle Scholar
  31. 31.
    Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98(6):2277–84.  https://doi.org/10.1210/jc.2012-3582.CrossRefPubMedGoogle Scholar
  32. 32.
    Hirsch D, Shimon I, Manisterski Y, et al. Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s. Endocrine. 2018.  https://doi.org/10.1007/s12020-018-1709-y.CrossRefPubMedGoogle Scholar
  33. 33.
    Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202.  https://doi.org/10.1291/hypres.27.193.CrossRefPubMedGoogle Scholar
  34. 34.
    Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev. 1998;19(5):647–72.  https://doi.org/10.1210/edrv.19.5.0346.CrossRefPubMedGoogle Scholar
  35. 35.
    Tirabassi G, Boscaro M, Arnaldi G. Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine. 2014;46(3):370–86.  https://doi.org/10.1007/s12020-013-0112-y.CrossRefPubMedGoogle Scholar
  36. 36.
    Ceccato F, Antonelli G, Barbot M, et al. The diagnostic performance of urinary free cortisol is better than the cortisol: cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC–MS/MS method in routine clinical practice. Eur J Endocrinol. 2014;171(1):1–7.  https://doi.org/10.1530/eje-14-0061.CrossRefPubMedGoogle Scholar
  37. 37.
    Ceccato F, Barbot M, Zilio M, et al. Screening tests for Cushing’s syndrome: urinary free cortisol role measured by LC–MS/MS. J Clin Endocrinol Metab. 2015;100(10):3856–61.  https://doi.org/10.1210/jc.2015-2507.CrossRefPubMedGoogle Scholar
  38. 38.
    Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC–MS/MS. J Endocrinol Investig. 2017;40(7):753–60.  https://doi.org/10.1007/s40618-017-0644-8.CrossRefGoogle Scholar
  39. 39.
    Raff H. Cushing’s syndrome: diagnosis and surveillance using salivary cortisol. Pituitary. 2012;15(1):64–70.  https://doi.org/10.1007/s11102-011-0333-0.CrossRefPubMedGoogle Scholar
  40. 40.
    Ceccato F, Barbot M, Zilio M, et al. Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur J Endocrinol. 2013;169(1):31–6.  https://doi.org/10.1530/eje-13-0159.CrossRefPubMedGoogle Scholar
  41. 41.
    Deutschbein T, Broecker-Preuss M, Flitsch J, et al. Salivary cortisol as a diagnostic tool for Cushing’s syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol. 2012;166(4):613.  https://doi.org/10.1530/EJE-11-0945.CrossRefPubMedGoogle Scholar
  42. 42.
    Ceccato F, Marcelli G, Martino M, et al. The diagnostic accuracy of increased late night salivary cortisol for Cushing’s syndrome: a real-life prospective study. J Endocrinol Investig. 2018.  https://doi.org/10.1007/s40618-018-0921-1.CrossRefGoogle Scholar
  43. 43.
    Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007;92(11):4123–9.  https://doi.org/10.1210/jc.2007-0596.CrossRefPubMedGoogle Scholar
  44. 44.
    Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553–62.  https://doi.org/10.1210/jc.2008-0139.CrossRefPubMedGoogle Scholar
  45. 45.
    Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(12):4851–9.  https://doi.org/10.1210/jc.2009-1500.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31.  https://doi.org/10.1210/jc.2015-1818.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ceccato F, Barbot M, Zilio M, Albiger N, Mantero F, Scaroni C. Therapeutic strategies for Cushing’s syndrome: an update. Expert Opin Orphan Drugs. 2015;3(1):45–56.  https://doi.org/10.1517/21678707.2015.991714.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Endocrinology Unit, Department of Medicine DIMEDUniversity-Hospital of PadovaPadovaItaly

Personalised recommendations